Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3606175 | 0.86 | ALDH1A1 (0.41) | RAB9ATSHRALDH1A1CYP3A4CYP2C19 | |
| SCHEMBL3599574 | 0.83 | SMN1; SMN2 (0.35) | PIK3CDTSHRSMN1; SMN2ALDH1A1CYP3A4 | |
| SCHEMBL3603382 | 0.83 | PPM1B (0.38) | PIK3CDTSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL3611663 | 0.83 | HTT (0.34) | PIK3CDRAB9ATSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL3609815 | 0.83 | PIK3CD (0.38) | PIK3CDRAB9ATSHRALDH1A1 | |
| SCHEMBL3605651 | 0.81 | SMN1; SMN2 (0.43) | RAB9ATSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL3589754 | 0.79 | RECQL (0.38) | TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL5359662 | 0.77 | ADRB2 (0.43) | PIK3CDRAB9ATSHRALDH1A1 | |
| SCHEMBL9158029 | 0.74 | TSHR (0.46) | RAB9ATSHRSMN1; SMN2ALDH1A1CYP3A4 | |
| SCHEMBL23295632 | 0.73 | L3MBTL1 (0.39) | RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7741497-B2 | Processes for preparing alkyl 3-(4-tetrahydropyranyl)-3-oxopropanoate compound and 4-acyltetrahydropyrane | UBE INDUSTRIES, LTD. (JP) | 2010-06-22 | — | — | US | disclosed |
| US-20070043107-A1 | Processes for preparing alkyl 3-(4-tetrahydropyranyl)-3-oxopropanoate compound and 4-acyltetrahydropyrane | UBE INDUSTRIES, LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1700852-A1 | PROCESSES FOR PRODUCING ALKYL 3-(4-TETRAHYDROPYRANYL)-3-OXOPROPIONATE COMPOUND AND 4-ACYLTETRAHYDROPYRAN | Ube Industries, Ltd. (JP) | 2006-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043107-A1 | Processes for preparing alkyl 3-(4-tetrahydropyranyl)-3-oxopropanoate compound and 4-acyltetrahydropyrane | DHPS, OXER1, CYP4A11 | PIK3CD 993/4885RAB9A 3231/4885TSHR 3572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.